Everything below concerns amino acid substitution. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Austin participated in the Royal Rumble match, where he was the last wrestler eliminated by the winner Mr. McMahon. Austin defeated McMahon St. Valentine's Day Massacre in a steel cage match, winning the championship opportunity at WrestleMania XV, where he defeated The Rock to win his third WWF Championship. Austin faced The Rock in a rematch the following month at Backlash. Austin would lose the championship to The Undertaker at Over the Edge. Due to events revolving around Vince, Stephanie and Linda McMahon made Austin the chief executive officer (CEO) of the company as part of the storyline. Vince and Shane challenged Austin to a handicap ladder match at King of the Ring with the title of CEO on the line, which the McMahons won. The next night on Raw, Austin challenged and defeated The Undertaker to win his fourth WWF Championship. The two would compete in a "First Blood" match at Fully Loaded, with the stipulation that if Austin lost he would never compete for the WWF Championship again, but if Austin won, Vince would depart the company; Austin won after interference from X-Pac.
==== The "disorganized crime" and choice theses ==== One of the most important trends to emerge in criminological thinking about OC in recent years is the suggestion that it is not, in a formal sense, "organized" at all. Evidence includes lack of centralized control, absence of formal lines of communication, fragmented organizational structure. It is distinctively disorganized. For example, Seattle's crime network in the 1970s and 80s consisted of groups of businessmen, politicians and of law enforcement officers. They all had links to a national network via Meyer Lansky, who was powerful, but there was no evidence that Lansky or anyone else exercised centralized control over them. While some crime involved well-known criminal hierarchies in the city, criminal activity was not subject to central management by these hierarchies nor by other controlling groups, nor were activities limited to a finite number of objectives. The networks of criminals involved with the crimes did not exhibit organizational cohesion. Too much emphasis had been placed on the Mafia as controlling OC. The Mafia were certainly powerful but they "were part of a heterogeneous underworld, a network characterized by complex webs of relationships." OC groups were violent and aimed at making money but because of the lack of structure and fragmentation of objectives, they were "disorganized". Further studies showed neither bureaucracy nor kinship groups are the primary structure of organized crime; rather, the primary structures were found to lie in partnerships or a series of joint business ventures.
2011: Icon acquired Oxford Outcomes, an international health outcomes consultancy and Firecrest Clinical, a technology provider specialising in site performance and study management 2012: Icon acquired PriceSpective, a global value strategy consultancy and Chinese CRO, BeijingWits 2013: Icon acquired staffing and FSP providers, ClinForce and Assent and Akos, an EU provider of pharmacovigilance and drug safety services 2014: Icon acquired Aptiv Solutions, a market leader in adaptive trial design and execution 2015: Icon acquired MediMedia Pharma Solutions to enhance market access and scientific communications capabilities, and PMG Research Inc., an integrated network of clinical research sites in the US 2016: Icon acquired Clinical Research Management Inc., to extend its presence in the government-sponsored research market 2017: Icon acquired MAPI Group, thereby becoming the world's second-largest provider of late-phase services 2019: Icon acquired Symphony Clinical Research, a leading provider of at-home patient services and site-support services; MediNova, an integrated network of clinical research sites across EMEA; and MolecularMD, to enhance its laboratory offerings in molecular diagnostic testing and immunohistochemistry 2020: Icon acquired MedPass International, a leading European medical device CRO, regulatory and reimbursement consultancy 2021: Icon acquired PRA Health Sciences, a competitor offering clinical research services, for US$12 billion.
==== Belief propagation ==== In belief propagation for protein design, the algorithm exchanges messages that describe the belief that each residue has about the probability of each rotamer in neighboring residues. The algorithm updates messages on every iteration and iterates until convergence or until a fixed number of iterations. Convergence is not guaranteed in protein design. The message mi→ j(rj that a residue i sends to every rotamer (rj at neighboring residue j is defined as:
Sources: en.wikipedia.org
== Medical uses == Hydroxyzine is used in the treatment of itchiness, anxiety, and nausea due to motion sickness. A systematic review concluded that hydroxyzine outperforms placebo in treating generalized anxiety disorder. Insufficient data were available to compare the drug with benzodiazepines and buspirone. Hydroxyzine can also be used for the treatment of allergic conditions, such as chronic urticaria, atopic or contact dermatoses, and histamine-mediated pruritus. These have also been confirmed in both recent and past studies to have no adverse effects on the liver, blood, nervous system, or urinary tract. Use of hydroxyzine for premedication as a sedative has no effects on tropane alkaloids, such as atropine, but may, following general anesthesia, potentiate meperidine and barbiturates, and use in pre-anesthetic adjunctive therapy should be modified depending upon the state of the individual. Doses of hydroxyzine hydrochloride used for sleep range from 25 to 100 mg. As with other antihistamine sleep aids, hydroxyzine is usually only prescribed for short term or "as-needed" use since tolerance to the central nervous system (CNS) effects of hydroxyzine can develop in as little as a few days. A major systematic review and network meta-analysis of medications for the treatment of insomnia published in 2022 found little evidence to inform the use of hydroxyzine for insomnia. A 2023 meta-review concludes that hydroxyzine is effective for inducing sleep onset but less effective for maintaining sleep for eight hours.
== Medical uses == Fosaprepitant is indicated for people aged six months of age and older, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin; and for delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
1996: Rozman Jusoh and Razali Mat Zin, both Malaysian odd-job labourers, hanged on 12 April 1996 for trafficking a total of nearly 2 kg of marijuana. 1999: Chua Gin Boon, hanged on 25 June 1999 for trafficking 60g of heroin. 2003: Vignes Mourthi and Moorthy Angappan, the two Malaysians hanged on 26 September 2003 for smuggling 27.65g of diamorphine. 2004: Yen May Woen, a Singaporean hairdresser hanged on 19 March 2004 for trafficking 30 grams of pure heroin 2005: Shanmugam Murugesu, a Singaporean former athlete and military man hanged on 13 May 2005 for smuggling 1 kg of cannabis. 2005: Nguyen Tuong-van, an Australian hanged on 2 December 2005 for smuggling 396.2 grams of diamorphine (pure heroin). 2007: Iwuchukwu Amara Tochi and Okeke Nelson Malachy, two Nigerians hanged on 26 January 2007 for smuggling diamorphine. 2022: Abdul Kahar Othman, a Singaporean who was executed on 30 March 2022 for trafficking 66.77g of diamorphine in 2010. Abdul Kahar was a first convict to be hanged during COVID Pandemic. 2022: Nagaenthran K.
Debridement is the medical removal of dead, damaged, or infected tissue to improve the healing potential of the remaining healthy tissue. Removal may be surgical, mechanical, chemical, autolytic (self-digestion), or by maggot therapy. In podiatry, practitioners such as chiropodists, podiatrists and foot health practitioners remove conditions such as calluses and verrucas. Debridement is an important part of the healing process for burns and other serious wounds; it is also used for treating some kinds of snake and spider bites. Sometimes the boundaries of the problem tissue may not be clearly defined. For example, when excising a tumor, there may be micrometastases along the edges of the tumor that are too small to be detected, but if not removed, could cause a relapse. In such circumstances, a surgeon may opt to debride a portion of the surrounding healthy tissue to ensure that the tumor is completely removed.
=== Cellular localization === Several factors that regulate eIF4E functions also modulate the subcellular localization of eIF4E. For instance, overexpression of PRH/Hex leads to cytoplasmic retention of eIF4E, and thus loss of its mRNA export activity and suppression of transformation. PML overexpression leads to sequestration of eIF4E to nuclear bodies with PML and decrease of eIF4E nuclear bodies containing RNA, which correlates to repressed eIF4E dependent mRNA export and can be modulated by stress. Overexpression of LRPPRC reduces eIF4E's co-localization with PML in the nucleus and leads to increased mRNA export activity of eIF4E. As discussed above, Importin 8 brings eIF4E into the nucleus and its overexpression stimulates the RNA export and oncogenic transformation activities of eIF4E in cell lines. Transduction of primary AML cells with IkB-SR resulted not only in reduction of eIF4E mRNA levels, but also re-localization of eIF4E protein.
Sources: en.wikipedia.org
The Sam and Ann Barshop Institute for Longevity and Aging Studies is a basic and clinical research institute located on the Greehey Academic and Research Campus of the University of Texas Health Science Center at San Antonio (UTHSCSA). It is a leading institute in the United States in geriatrics research. The Barshop Institute ranks #1 in National Institute on Aging funding among Texas institutions and is highly ranked in the country in National Institute of Health funding. The scientific director of the institute has been Elena Volpi, M.D., PhD, FGSA since July 2023. In 2009, one of the research projects of the institute was announced by Science magazine as one of the top scientific discoveries of the year. The Barshop Institute is home to several prestigious National Institute on Aging (NIA) research centers and programs, including the Nathan Shock Center, the Claude D. Pepper Older Americans Independence Center, the Center for Alzheimer's Disease and Related Dementias Population Aging and Social Studies, and the Interventions Testing Program. Collectively, these NIH-supported initiatives advance the Institute's mission to uncover the biological mechanisms of aging, develop interventions that prevent or treat age-related diseases, and promote healthier aging across the lifespan.
History of chemical physics – history of the branch of physics that studies chemical processes from the point of view of physics and engineering. History of oenology – history of the science and study of all aspects of wine and winemaking except vine-growing and grape-harvesting, which is a subfield called viticulture. History of spectroscopy – history of the study of the interaction between matter and radiated energy History of surface science – history of the study of physical and chemical phenomena that occur at the interface of two phases, including solid–liquid interfaces, solid–gas interfaces, solid–vacuum interfaces, and liquid–gas interfaces. History of chemicals History of chemical elements - The concept of an "element" as an indivisible substance has developed through three major historical phases: Classical definitions (such as those of the ancient Greeks), chemical definitions, and atomic definitions. History of carbon History of hydrogen Timeline of hydrogen technologies History of oxygen History of chemical products History of aspirin History of cosmetics History of gunpowder History of pharmaceutical drugs History of vitamins History of chemical processes History of manufactured gas History of the Haber process History of the chemical industry History of the petroleum industry History of the pharmaceutical industry History of the periodic table
Olaf College Elio Di Rupo (born 1951), Prime Minister of Belgium Israel Shahak (1933–2001), Israeli chemist and civil-rights activist Margaret Thatcher (1925–2013), Prime Minister of the United Kingdom (1979–1990), research chemist at BX Plastics
Organoselenium chemistry is the science exploring the properties and reactivity of organoselenium compounds, chemical compounds containing carbon-to-selenium chemical bonds. Selenium belongs with oxygen and sulfur to the group 16 elements or chalcogens, and similarities in chemistry are to be expected. Organoselenium compounds are found at trace levels in ambient waters, soils and sediments. Selenium can exist with oxidation state −2, +2, +4, +6. Se(II) is the dominant form in organoselenium chemistry. Down the group 16 column, the bond strength becomes increasingly weaker (234 kJ/mol for the C−Se bond and 272 kJ/mol for the C−S bond) and the bond lengths longer (C−Se 198 pm, C−S 181 pm and C−O 141 pm). Consistent with the inertness of large-n s orbitals, dicoordinate selenium compounds have a bond angle of nearly 90°. Selenium compounds are more nucleophilic than the corresponding sulfur compounds and also more acidic. The pKa values of XH2 are 16 for oxygen, 7 for sulfur and 3.8 for selenium. In contrast to sulfoxides, the corresponding selenoxides are unstable in the presence of β-protons and this property is utilized in many organic reactions of selenium, notably in selenoxide oxidations and in selenoxide eliminations. The first organoselenium compound to be isolated was diethyl selenide in 1836.
Aleniglipron (development code GSBR-1290) is a small-molecule GLP-1 agonist developed by Structure Therapeutics. It is delivered orally and is in a Phase II trial as of 2023. In June 2024, Structure Therapeutics reported positive topline data from a Phase 2a obesity study in which GSBR-1290 demonstrated clinically meaningful and statistically significant placebo-adjusted mean weight loss and generally favorable safety and tolerability results.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.